Gro-Vida
Portuguese medical cannabis cultivator with limited public documentation and B2B focus.
Gro-Vida appears in trade coverage as a Portuguese cultivator supplying EU-grown flower to larger cannabis companies, but independent verification of ownership, facility details, products, and certifications is sparse. If you encounter Gro-Vida in a supply chain or product label, check the actual licence, GMP certificate, and batch test—not the cultivator's marketing claims. Small B2B cannabis operators receive little public scrutiny.
What can be verified
Gro-Vida is named in trade press as a Portugal-based cannabis cultivator operating in the country's medical cannabis sector, which is regulated by INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde). Portugal permits licensed cultivation, manufacture, and export of cannabis-based medicines under INFARMED authorisation. The company has been mentioned in reporting as a supplier of EU-grown flower to Canopy Growth Corporation, the Canadian cannabis company that owns the Tweed brand [1].
Beyond this, independent details about Gro-Vida's facility size, ownership structure, cultivation methods, certifications, strains, or product specifications are not consistently documented in publicly accessible sources as of October 2026 No data. The company does not appear to operate a public consumer website, strain database, or product catalogue. It functions as a business-to-business supplier; end consumers do not purchase products under the "Gro-Vida" label.
What the name suggests—and why that is not evidence
Cannabis strain and brand names in the legal market are not standardised, regulated, or reliably linked to specific genetics or origins [2]. A company name like "Gro-Vida" (suggesting growth or life) tells you nothing about the actual cultivars grown, cannabinoid profiles, terpene composition, or sourcing claims. Similarly, references to "Portuguese," "EU-grown," or "pharmaceutical-grade" are marketing language, not regulated claims Anecdote.
Strain names such as "Green Crack," "OG Kush," or "Super Lemon Haze" are used by multiple producers with no enforcement of genetic consistency across suppliers Weak / limited [2]. If you see a product labelled as Gro-Vida or sourced from Gro-Vida, the label itself and accompanying batch test—not the brand name or origin story—determine what you are actually buying.
What to check if you encounter Gro-Vida products
If a product is marketed as sourced from, cultivated by, or supplied by Gro-Vida, independently verify the following before relying on any claims:
- Current INFARMED licence: Confirm that Gro-Vida holds an active cultivation and/or manufacture licence by contacting INFARMED directly or checking their public registry.
- EU-GMP certification: Medical cannabis cultivators in the EU must hold EU-GMP certification. Check the EudraGMDP database for the certificate holder, scope (cultivation, packaging, batch release), issuing authority, and expiry date [3].
- Batch certificate of analysis (CoA): Request the lab report for the specific batch you are considering. It should detail cannabinoid potency (THC, CBD), pesticide residues, heavy metals, microbial load, and residual solvents, issued by an accredited laboratory.
- Destination-country import authorisation: Cannabis products exported from Portugal must comply with the import regulations of the destination country (Germany, UK, Poland, etc.). Verify that the product holds the necessary permits.
- Actual supply chain: The cultivator, processor, packager, and marketing-authorisation holder may be separate entities. Confirm which company holds the marketing authorisation and is responsible for the finished product.
Marketing language such as "premium," "sustainable," "craft," or "pharmaceutical-grade" is not regulated and should not substitute for documentary evidence.
Ownership and regulatory status
Gro-Vida's ultimate ownership, shareholder structure, and any parent-company relationships are not clearly established in publicly accessible sources No data. Portuguese companies must be registered in the Portuguese commercial registry (Registo Comercial); that registry is the authoritative source for shareholder and director information, but is not consistently reported in international trade press or cannabis industry databases.
Based on available reporting, Gro-Vida is not a subsidiary of Canopy Growth. The publicly described relationship is a supply agreement, not an acquisition [1]. Canopy Growth's own regulatory filings (SEC Form 10-K, Canadian annual information forms) list consolidated subsidiaries; Gro-Vida does not appear on those lists Weak / limited [4].
Gro-Vida does not appear in major cannabis industry controversies or regulatory enforcement actions reported in English-language media as of October 2026 No data. Absence of negative coverage is not evidence of a clean record; small B2B cultivators receive limited journalistic scrutiny, and Portuguese regulatory actions are not always reported internationally.
Availability and market context
EU-grown medical cannabis is exported under INFARMED-issued export authorisations to other EU member states and certain non-EU countries that accept EU-GMP-certified products, subject to import permits. Germany has been the dominant destination market for EU-grown medical cannabis since 2017, when cannabis-based medicines became eligible for prescription dispensing in German pharmacies [1].
Gro-Vida product does not reach consumers as a retail brand. Any Gro-Vida-sourced flower reaches patients through licensed pharmacies (in Germany), specialist clinics (in the UK), or equivalent medical-access channels, under the branding of the marketing-authorisation holder or distributor—not under the "Gro-Vida" label.
Portugal itself has no legal recreational cannabis market. Personal possession of small quantities is decriminalised under Portugal's 2001 drug-policy reform, but commercial supply for non-medical use remains illegal Strong evidence [5].
How to report corrections or new information
This profile reflects publicly available information as of October 2026. If you have verifiable documentary evidence that corrects, updates, or adds to this profile—such as a current INFARMED licence record, EU-GMP certificate, corporate registry listing, published interview, or batch certificate of analysis—you are invited to flag it via the Weedpedia error-reporting system. Links to official registries, peer-reviewed sources, or established news outlets are preferred. Anonymous tips are accepted but will be weighted less heavily than on-the-record information.
Sources
- Reported Reuters. Portugal becomes a medical cannabis hub for Europe. 2023.
- Peer-reviewed Raber JC, Elzinga S, Kaplan C. Understanding dabs: contamination concerns with cannabis concentrates and cannabinoid transfer during smoking. Journal of Toxicological Sciences, 2015; 40(6): 797–803.
- Government European Medicines Agency. EudraGMDP — public database of GMP/GDP certificates and manufacturing authorisations.
- Government Canopy Growth Corporation. Annual Report (Form 10-K), filed with U.S. Securities and Exchange Commission.
- Peer-reviewed Hughes CE, Stevens A. What can we learn from the Portuguese decriminalization of illicit drugs? British Journal of Criminology, 2010; 50(6): 999–1022.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Aurora Cannabis — Canadian licensed producer pivoting toward medical cannabis and international export.
- Cansativa — German medical cannabis wholesaler and exclusive distributor of state-cultivated cannabis.
- Linneo Health — Spanish medical cannabis cultivator with AEMPS license; exports to regulated markets.